Wednesday , 1 April 2015

style="display:inline-block;width:728px;height:90px" data-ad-client="ca-pub-1321263602293216" data-ad-slot="6141371951">
Home » Health » Merck's HIV patent agreement ignites monopoly criticism – SciDev.Net

Merck's HIV patent agreement ignites monopoly criticism – SciDev.Net

Merck’s HIV patent agreement ignites monopoly criticism
SciDev.Net
The MPP and Merck signed a licensing agreement last month (24 February) for paediatric formulations of raltegravir, one of the few HIV drugs approved for children younger than three. Using the new licence, drug manufacturers can make cheaper versions

Merck's HIV patent agreement ignites monopoly criticism – SciDev.Net Reviewed by on . Merck's HIV patent agreement ignites monopoly criticismSciDev.NetThe MPP and Merck signed a licensing agreement last month (24 February) for paediatric formulat Merck's HIV patent agreement ignites monopoly criticismSciDev.NetThe MPP and Merck signed a licensing agreement last month (24 February) for paediatric formulat Rating:
scroll to top